Expression and localisation of osteopontin and prominin-1 (CD133) in patients with endometriosis

FABIO D’AMICO1, EVANGELIA SKARMOUTSO1, GIUSEPPE QUADERNO1, GRAZIA MALAPONTE1, CARMELO LA CORTE2, GIUSEPPE SCIBILIA3, GABRIELLA D’AGATE3, PAOLO SCOLLO3, FILIPPO FRAGGETTA2, DEMETRIOS A. SPANDIDOS4 and MARIA CLORINDA MAZZARINO1

1Department of Biomedical Sciences, Pathology and Oncology Unit, University of Catania; 2Pathology Unit and 3Department of Obstetrics and Gynecology, Cannizzaro Hospital, Catania, Italy; 4Laboratory of Clinical Virology, Faculty of Medicine, University of Crete, Heraklion, Crete, Greece

Received March 14, 2013; Accepted March 28, 2013

DOI: 10.3892/ijmm.2013.1325

Abstract. In this study, we investigated the expression and localisation of the proteins, osteopontin (OPN) and prominin-1 (CD133), as well as the plasma OPN levels in the endometrium of patients with endometriosis. Samples of ectopic endometriotic lesions and normal endometrium were obtained from 31 women with endometriosis and 28 healthy control subjects. The mRNA and protein expression of OPN and CD133 was analysed by real-time RT-PCR and immunohistochemistry. The plasma levels of OPN were determined by ELISA. Our results revealed that OPN mRNA and protein expression, as well as its release in the blood, was significantly increased in the endometriotic lesions in comparison to normal tissue. Although the presence of CD133+ cells was detected in the normal endometrium, as well as in the endometriosis specimens, a significant quantitative variation of this protein was not demonstrated in the patients with endometriosis. In conclusion, our data indicate that OPN is involved in the development of endometriosis by enhancing the invasiveness, proliferation and survival of endometrial cells in ectopic lesions. CD133 cannot be used as a disease marker for endometriosis, although an involvement of this protein in the pathogenesis of endometriosis cannot be excluded.

Introduction

Endometriosis is a complex and chronic gynecological disorder characterised by the presence of endometrial tissue outside the uterus (1). Genetic, hormonal and environmental factors contribute to the susceptibility to endometriosis; however, the pathogenesis of this disease has not yet been fully elucidated.

Although endometriotic cells are not characterised by uncontrolled proliferation, they show some properties of malignant tissues, such as invasion, induction of metastasis, and the ability to evade apoptosis (2,3). In particular, it is known that the ability of endometriotic cells to invade surrounding tissue is induced by a group of proteins termed metastasis-inducing proteins (MIPs), such as osteopontin (OPN) (4).

OPN, a 70-kDa secreted glycoprotein, is mainly involved in cell adhesion and migration (5), and it has been found to be expressed in endometrial epithelium in normally cycling fertile women (6). However, various studies on the endometrial expression of OPN in patients with endometriosis have provided controversial results. A previous study demonstrated that the OPN protein is densely expressed in eutopic normal endometrium, as well as in epithelial cells of endometriotic cysts (7). Moreover, OPN mRNA expression, as well as its plasma levels, have been shown to be higher in patients with endometriosis compared to normal subjects (8). It has been reported that OPN mRNA levels are reduced during the early secretory phase of women with moderate-to-severe endometriosis (9,10).

Another feature of endometriosis is represented by its stem cell origin (11). It has been hypothesised that endometriosis may be caused by a dysregulation of stem cell function (12).

Prominin-1 (CD133), a stem cell-associated antigen, is a 120-kDa glycoprotein, and a member of the prominin family of pentaspan membrane proteins (13). CD133 has been shown to be localised in glandular and luminal epithelial cells of the normal endometrium (14).

The spreading of endometrial epithelial progenitor cells may represent one of the mechanisms involved in the pathogenesis of endometriosis, a disease characterised by a dense vascularisation of its lesions (15). It is known that OPN may influence the angiogenesis, proliferation and migration of endothelial progenitor cells, acting as a regulator of CD133+ progenitor cells (16,17).

The present study aimed to determine whether OPN and CD133 expression is altered in the human ectopic endometrium, and whether the expression of these two molecules correlates with the clinical features of endometriosis. The expression profiles of OPN and CD133 were analysed in ectopic lesions, as well as in normal endometrium by real-time RT-PCR and
immunohistochemistry. Furthermore, we also evaluated the plasma levels of OPN in patients with endometriosis.

Materials and methods

Patient selection. Sixty-one women were enrolled in this study after providing written informed consent. Thirty-one patients underwent laparoscopic surgery at the Department of Obstetrics and Gynecology, Cannizzaro Hospital, Catania, Italy. As control subjects, 30 women with benign non-endometriotic ovarian cysts were enrolled in this study. Clinical data including, age, history of pregnancy, parity, body mass index (BMI) and serum cysts were collected at surgery. Endometriosis was confirmed by a histopathological examination of samples and the extent of the disease was evaluated according to the revised classification of endometriosis provided by the American Society of Reproductive Medicine (18). Twenty-two cases were classified as minimal-to-mild disease (stage I and II) and 9 cases were classified as moderate-to-severe disease (stage III and IV). All the patients were in the proliferative phase of the menstrual cycle. The study protocol was approved by the local ethics committee.

RNA extraction and real-time RT-PCR. Fresh endometrial specimens were immediately transferred in RNeAlater™ (Sigma-Aldrich, St. Louis, MO, USA) and stored at -80˚C until RNA extraction. Tissue specimens were pulverised and then dissolved in TRIZol reagent (Invitrogen, Carlsbad, CA, USA), according the manufacturer's instructions. The concentration of the purified RNA was determined by spectrophotometry. For further analysis, equal RNA loading and integrity was confirmed by showing consistent intensities of 28S and 18S rRNA bands on RNase-free agarose gel electrophoresis. A total of 2 µg of RNA from each sample was reverse transcribed into cDNA using the SuperScript III First-Strand Synthesis System (Invitrogen) according to the manufacturer's instructions.

mRNA expression was measured by SYBR-Green quantitative real-time RT-PCR using the Rotor-Gene Q thermal cycler (Qiagen, Valencia, CA, USA). The primers used for PCR amplification were: CD133 forward, TTTCAGGACTTCCGAACCTCTTCTTT and reverse, GACAGGGATGATGGTGGGCTCTCA (167 bp); OPN forward, AGACCTGACATCCAACTCTCTT and reverse, GAACAGGGATGATGTTGGG (188 bp). The PCR reaction was carried out in 25 µl buffer, containing 50 ng cDNA, 1 µM of each primer and 12.5 µl 2X Rotor-Gene SYBR-Green PCR Master Mix (Qiagen). The thermal cycling conditions were as follows: denaturation at 95˚C for 5 min, followed by 40 cycles of denaturation for 10 sec at 95˚C and annealing and extension for 15 sec at 60˚C. As the housekeeping gene, glyceraldehyde-3-phosphate dehydrogenase (GADPH; QuantiTect Primer assay, Qiagen) was amplified in order to normalise the amount of total RNA present in each reaction. The quantification of the transcripts was carried out utilizing the dComparative Quantitation™ software supplied with Rotor-Gene Q. Endometrial tissue from a normal subject was used as calibrator, and the mean efficiency of the take-off point of the cycling curves was used to calculate the fold change according to the formula: fold change= efficiencyCt1/efficiencyCt2, where Ct1 and Ct2 are the take-off values of the cycling curves being compared. Each real-time RT-PCR reaction was conducted in duplicate, in order to evaluate data reproducibility. The results are expressed as means ± SEM and the Student's t-test was used to compare the means of two samples. Significance was accepted at the 5% level.

Plasma OPN measurement. Peripheral blood samples were collected from patients with endometriosis and control subjects by venous puncture, and immediately centrifuged at 1,500 x g at +4˚C for 10 min. Plasma was stored at -80˚C until analysis. Plasma OPN levels were measured using the commercially available Quantikine™ Human Osteopontin ELISA kit (R&D Systems, Minneapolis, MN, USA), according to the manufacturer's instructions. Samples were run in duplicate, and the results are expressed in ng/ml. Data are presented as the means ± SEM. The Student's t-test was used to compare the means of two samples. Significance was accepted at the 5% level.

Immunohistochemical analysis. Five-micrometer-thick paraffin-embedded sections were mounted on silanized slides. Following section deparaffinization and rehydration through a graded ethanol series at room temperature, antigen retrieval was performed in Tris-EDTA buffer (pH 9.0, 30 min) and in citrate buffer (pH 6.0, 20 min, 20 min) for OPN and CD133 immuno- staining, respectively. As primary antibodies, rabbit polyclonal anti-OPN, diluted 1:1,000 (AB1870; Chemicon, Temecula, CA, USA) and anti-prominin-1, diluted 1:200 (PAB12663; Abnova, Taipei, Taiwan) were used. All the immunohistochemical steps were carried out by the fully automated Menarini Bond™ autostainer (Menarini Diagnostics, Florence, Italy). For the controls, the primary antibody was substituted with non-immune serum and the primary antibody was omitted, thus incubating the slides only with buffer. For the evaluation of immunoreactivity, staining intensities were scored on the basis of the percentage of positive cells for OPN and CD133 as follows: -, <5%; +, 5-50%; and ++, >50%. Immunohistochemical semiquantitative analysis was performed by comparing the results using the χ2 test. A p-value <0.05 was considered to indicate a statistically significant difference.

Results

Clinical and demographic features of patients with endometriosis and control subjects. Table I displays the demographic and clinical characteristics of the patients and the control subjects. The mean age of the patients affected by endometriosis and the controls was 36.45 years (SD ±9.18) and 33.77 years (SD ±8.09), respectively. The mean number of pregnancies, as well as the parity was not statistically significant between the patients and the healthy control subjects. The difference in BMI between the patients and control groups was not significant. Finally, serum CA125 levels were higher in the patients in comparison to the controls: 59.44±45.56 vs. 19.37±21.97 IU/ml, respectively (p=0.0001).

mRNA expression of OPN and CD133. The mRNA expression of OPN and CD133 in the control and ectopic endometrial tissues was examined by quantitative real-time RT-PCR. As shown in Fig. 1A, OPN mRNA expression was significantly
higher in the patients with endometriosis compared to the controls: (3.79±1.30-fold increase vs. control subjects, p<0.01). A comparison of CD133 mRNA expression between the patients with endometriosis and the controls did not reveal any significant difference (Fig. 1B). A comparison of the OPN mRNA levels between the patients with stage I-II disease and those with stage III-IV disease did not reveal any significant difference (p=0.24) (data not shown).

**Plasma OPN levels.** As shown in Fig. 2, plasma OPN levels (means ± SEM) were higher in patients with endometriosis in comparison to the controls (602.3±125.7 vs. 375.1±53.2 ng/ml; p<0.01). A comparison of the OPN plasma levels between the patients with stage I-II disease and those with stage III-IV disease and the control group revealed similar results to those obtained between the total number of patients and the control group. Finally, a comparison of the plasma OPN levels between the patients with stage I-II disease and those with stage III-IV disease revealed no significant difference (data not shown).

We analysed the correlation between plasma OPN and serum CA125 levels. A positive correlation between plasma OPN and serum CA125 levels was observed in the total number of endometriosis patients (Pearson's test, r=0.41, p<0.05). However, a comparison between the 2 groups of patients (those with stage I-II and stage III-IV disease) did not reveal any statistically significant difference.

**OPN and CD133 immunohistochemical analysis.** In control sections, OPN immunostaining was localised in the cytoplasm of epithelial cells of the functional layer. Stromal cells were devoid of immunostaining for OPN (Fig. 3a). In the endometriotic tissue, OPN expression was higher in comparison to the control samples, and was localised in the cytoplasm of epithelial gland cells, as well as in several stromal macrophages (Fig. 3b). CD133 immunostaining in the control samples was exclusively localised on the surface of the epithelial cells lining the lumen of the functional layer (Fig. 3c). No immunostaining for CD133 was observed in the stroma. In the endometriotic lesion tissue, the immunohistochemical pattern for CD133 was similar to that observed in the control tissue (Fig. 3d). The results of the analysis of the intensity of the immunohistochemical reactions for OPN and CD133 are summarised in Table II.

| Characteristics         | Control subjects (n=30) | Patients with endometriosis (n=31) | P-value |
|-------------------------|------------------------|-----------------------------------|---------|
| Age, years              | 33.77±8.09             | 36.45±9.18                        | 0.25    |
| Number of pregnancies   | 0.74±1.02              | 0.93±1.39                         | 0.56    |
| Parity                  | 0.59±0.89              | 0.86±1.27                         | 0.36    |
| Serum CA125 levels      | 19.37±21.97            | 59.44±45.56                       | 0.0001  |
| BMI m²/kg               | 24.51±2.53             | 23.32±7.56                        | 0.44    |

Values are expressed as the means ± SD. The Student's t-test was used for statistical comparisons between 2 groups. BMI, body mass index.
Comparison of clinical findings of patients with endometriosis according to the severity of disease. No significant differences were observed between the age, number of pregnancies, parity, serum CA125 levels and BMI of the patients with endometriosis with stage I-II and stage III-IV disease. In particular, the mean age was 36±2.48 years in the patients with stage I-II disease vs. 35.75±5.94 years in the patients with stage III-IV disease (p=0.96); the number of pregnancies was 1.40±0.40 in the patients with stage I-II disease vs. 1.67±0.89 in the patients with stage III-IV disease (p=0.75); parity was 1.20±0.28 in the patients with stage I-II disease vs. 1.34±0.67 in the patients with stage III-IV disease (p=0.82); serum CA125 levels were 47.71±7.72 IU/ml in the patients with stage I-II disease vs. 72.96±38.74 IU/ml in the patients with stage III-IV disease (p=0.36); BMI was 25.28±3.08 m²/kg in the patients with stage I-II disease vs. 20.07±3.30 m²/kg in the patients with stage III-IV disease (p=0.33).

Discussion

The pathological processes involved in endometriosis have not yet been fully elucidated. However, endometriosis has been found to be associated with changes in the expression of several genes, including cytokines (19), such as the multifunctional cytokine OPN, which has been intensively investigated in endometriosis (7,8,10,20).

The results from the present study revealed that OPN mRNA expression, as well as its release in the blood, was significantly increased in patients with endometriosis compared to normal patients. This finding is consistent with previous studies that have shown a correlation between OPN expression and the severity of endometriosis.

Table II. Evaluation of immunostaining intensity of OPN and CD133 in normal tissue and endometriotic lesions.

| Staining intensity | OPN  | CD133 |
|--------------------|------|-------|
|                   | n    | -     | +     | ++   | -     | +     | ++   |
| Control endometrium| 30   | 3     | 27    | 0    | 5     | 24    | 1    |
| Stage I-II endometriosis | 22   | 13    | 9     | 0    | p<0.01<sup>a</sup> | 4     | 18    | 0    | NS   |
| Stage III-IV endometriosis | 9    | 0     | 6     | 3    | p<0.01<sup>a</sup> | 2     | 7     | 0    | NS   |

Three ranges are utilised: -, <5%; +, 5-50%; and ++, >50%. A comparison of the results was performed using the χ² test (<sup>a</sup>statistically significant difference; NS, not significant). OPN, osteopontin; n, number of patients.
increased in endometriotic lesions in comparison to normal tissue. Our findings on OPN mRNA expression are in agreement with those of other studies, which have demonstrated an increased OPN mRNA expression, as well as increased OPN plasma levels in patients with endometriosis in comparison to control subjects, regardless of the phase of the menstrual cycle and diseases stage (8). Similarly, by means of oligonucleotide microarray analysis, complimentary DNA microarrays and quantitative real-time RT-PCR, OPN gene expression has been shown to be increased in endometriotic lesions in a rat model of endometriosis in comparison to normal rats (21,22). On the contrary, with the use of microarray analysis, a downregulation of OPN expression has been observed during the secretory phase in endometriotic lesions (9).

As regards immunohistochemical analysis, we found a higher semiquantitative expression of OPN in both groups of endometriosis patients (the first including patients with stage I-II disease and the second group including patients with stage III-IV disease) in comparison to the eutopic endometrium of the control subjects. Moreover, the OPN staining pattern obtained in the present study, was similar to that observed in the study by Odagiri et al (7), who demonstrated that this molecule was mainly immunolocallised in normal and ectopic endometrial epithelial cells. However, these authors did not find a significant difference in the staining intensity between endometriotic lesions and control samples. Moreover, another immunohistochemical study demonstrated different OPN expression intensities in endometriotic lesions in comparison to normal specimens, according to the histological grade (10). Recently, Casals et al (20) demonstrated no statistically significant difference in OPN expression between patients and the control subjects.

Such discrepancies may arise from the heterogeneity of the endometriotic samples included in the above studies. For this reason, we restricted the sampling of specimens from women who were in the proliferative phase, and subdivided the patients into 2 groups, one group including those patients with minimal-to-mild disease and the other group including patients with moderate-to-severe disease.

Since it is well known that the functional role of OPN includes cell adhesion, migration, differentiation and regulation of the metastatic spread of tumour cells, it can be hypothesised that the expression of OPN is increased in patients with endometriosis, which would enhance endometrial invasiveness, proliferation and survival in ectopic lesions.

A recent study revealed that a subset of endometriotic cells displayed certain features characteristic of somatic stem cells, such as the presence of CD133 (23). This cell subset seems to originate from bone marrow, and to display endothelial progenitor cell-like features (24). The proliferation and migration of endothelial progenitor cells are influenced by OPN (16,17), which may be required for the homing of these cells (25). OPN shows opposite effects depending on tissue and the physiological state of the cell. In general, OPN is a potent stimulator of cell proliferation, although it represents a negative regulator of hematopoietic stem cell proliferation (26). Possibly, such a mechanism may be mediated by β1-integrins (27), and OPN may induce a lateral organization of lipids and membrane proteins in lipid rafts (28), in order to activate associated signal transduction pathways (29). Although the role of CD133 in stem cells remains unclear, there is much evidence suggesting that this protein plays a potential role as an organiser of specific membrane domains (13), which seems essential for the maintenance of stem cell properties (30). Although we observed the presence of CD133+ cells in the normal endometrium, as well as in endometriosis specimens, we did not observe a significant quantitative variation of this protein in patients with endometriosis. However, the presence of the somatic stem cell marker, CD133, suggests the occurrence of a stem cell origin in the pathogenesis of the disease. There is emerging evidence for the occurrence of endometrial cancer stem cells within CD133+ and side population cells (31), which could explain the fact that endometriosis is associated with 10-15% of ovarian cancer cases (32).

Thus, further studies are required to determine whether CD133 is expressed and localised in endometrial stem cells, and whether this molecule may be used as a marker of stemness in the eutopic and ectopic endometrium.

In conclusion, the results from our study confirm that OPN is involved in the development of endometriosis by enhancing the invasiveness, proliferation and survival of endometrial cells in ectopic lesions. Furthermore, we suggest that the protein, CD133, cannot be used as a disease marker for endometriosis. Future studies are required in order to further clarify the possible role and specific mechanisms of action of these molecules in the pathogenesis of endometriosis, in order to improve the quality of life of patients with this debilitating and complex disease.

References

1. de Ziegler D, Borghese B and Chapron C: Endometriosis and infertility: pathophysiology and management. Lancet 376: 730-738, 2012.
2. Swierz LM: Role of endometriosis in cancer and tumor development. Ann NY Acad Sci 955: 281-292, 2002.
3. Borghese B, Mondon F, Noël JC, Fayt I, Mignot TM, Vaiman D and Chapron C: Gene expression profile for ectopic versus eutopic endometrium provides new insights into endometriosis oncogenic potential. Mol Endocrinol 22: 2557-2562, 2008.
4. Anborogh PH, Mutrie JC, Tuck AB and Chambers AF: Role of the metastasis-promoting protein osteopontin in the tumour microenvironment. J Cell Mol Med 14: 2037-2044, 2010.
5. Liaw L, Skinner MP, Raines EW, Ross R, Chersh DA, Schwartz SM and Giachelli CM: The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest 95: 713-724, 1995.
6. Apparao KB, Murray MJ, Fritz MA, Meyer WR, Chambers AF, Truong PR and Lessey BA: Osteopontin and its receptor alphav betah3 integrin are coexpressed in the human endometrium during the menstrual cycle but regulated differentially. J Clin Endocrinol Metab 86: 4991-5000, 2001.
7. Odagiri K, Konno R, Fujiwara H, Netsu S, Ohwada M, Shibahara H and Suzuki M: Immunohistochemical study of osteopontin and L-selectin in a rat endometriosis model and in human endometriosis. Fertil Steril 88: 1207-1211, 2007.
8. Cho S, Ahn YS, Choi YS, Seo SK, Nam A, Kim HY, Kim JH, Park KH, Cho DJ and Lee BS: Endometrial osteopontin mRNA expression and plasma osteopontin levels are increased in patients with endometriosis. Am J Reprod Immunol 61: 286-293, 2009.
9. Burney RO, Talbi S, Hamilton AE, Vo KC, Nyegaard M, Nezhat CR, Lessey BA and Giudice LC: Gene expression analysis of endometriosis reveals progesterone resistance and candidate susceptibility genes in women with endometriosis. Endocrinology 148: 3814-3826, 2007.
10. Wei Q, St Clair JB, Fu T, Stratton P and Nieman LK: Reduced expression of biomarkers associated with the implantation window in women with endometriosis. Fertil Steril 91: 1686-1691, 2009.
11. Götte M, Wolf M, Staebler A, Buchweitz O, Kelsch R, Schüring AN and Kiesel L: Increased expression of the adult stem cell marker Musashi-1 in endometriosis and endometrial carcinoma. J Pathol 215: 317-329, 2008.
12. Maruyama T and Yoshimura Y: Stem cell theory for the pathogenesis of endometriosis. Front Biosci (Elite Ed) 4: 2854-2863, 2012.
13. Corbeil D, Karbanová J, Fargeas CA and Jászai J: Prominin-1 (CD133): molecular and cellular features across species. Adv Exp Med Biol 777: 3-24, 2013.
14. Schwab KE, Hutchinson P and Gargett CE: Identification of surface markers for prospective isolation of human endometrial stromal colony-forming cells. Hum Reprod 23: 934-943, 2008.
15. Sasson IE and Taylor HS: Stem cells and the pathogenesis of endometriosis. Ann NY Acad Sci 1127: 106-115, 2008.
16. Wang Y, Yan W, Lu X, Qian C, Zhang J, Li P, Shi L, Zhao P, Fu Z, Pu P, Kang C, Jiang T, Liu N and You Y: Overexpression of osteopontin induces angiogenesis of endothelial progenitor cells via the avβ3/PI3K/AKT/eNOS/NO signaling pathway in glioma cells. Eur J Cell Biol 90: 642-648, 2011.
17. Yu M, Liu Q, Yi K, Wu L and Tan X: Effects of osteopontin on functional activity of late endothelial progenitor cells. J Cell Biochem 112: 1730-1736, 2011.
18. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril 67: 817-821, 1997.
19. Eyster KM, Klinkova O, Kennedy V and Hansen KA: Whole genome deoxyribonucleic acid microarray analysis of gene expression in ectopic versus eutopic endometrium. Fertil Steril 88: 1505-1533, 2007.
20. Casals G, Ordi J, Creus M, Fábregues F, Carmona F, Casamitjana R and Balasch J: Expression pattern of osteopontin and avβ3 integrin during the implantation window in infertile patients with early stages of endometriosis. Hum Reprod 27: 805-813, 2012.
21. Flores I, Rivera E, Ruiz LA, Santiago OI, Vernon MW and Appleyard CB: Molecular profiling of experimental endometriosis identified gene expression patterns in common with human disease. Fertil Steril 87: 1180-1199, 2007.
22. Konno R, Fujiwara H, Natsu S, Odagiri K, Shimane M, Nomura H and Suzuki M: Gene expression profiling of the rat endometriosis model. Am J Reprod Immunol 58: 330-343, 2007.
23. Chan RW, Ng EH and Yeung WS: Identification of cells with colony-forming activity, self-renewal capacity, and multipotency in ovarian endometriosis. Am J Pathol 178: 2832-2844, 2011.
24. Masuda H, Matsuzyki Y, Hiratsu E, Ono M, Nagoshima T, Kajitani T, Arase T, Oda H, Uchida H, Asada H, Ito M, Yoshimura Y, Maruyama T and Okano H: Stem cell-like properties of the endometrial side population: implication in endometrial regeneration. PLoS One 5: e10387, 2010.
25. Lecen LL, Filipe C, Billon A, Garny-Susini B, Jalvy S, Robbesyn F, Daret D, Allières C, Ritting SR, Werner N, Nickenig G, Deutsch U, Dufourcq P, Lenfant F, Desgranges C, Arnal JF and Gadeau AP: Estrogen-stimulated endothelial repair requires osteopontin. Arterioscler Thromb Vasc Biol 28: 2131-2136, 2008.
26. Stier S, Ko Y, Forkert R, Lutz C, Neuhaus T, Grunewald E, Cheng T, Dombkowski D, Calvi LM, Ritting SR and Scadden DT: Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J Exp Med 201: 1781-1791, 2005.
27. Nilsson SK, Johnston HM, Whitty GA, Williams B, Webb RJ, Denhardt DT, Bertoncello I, Bendall LJ, Simmons PJ and Haylock DN: Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood 106: 1232-1239, 2005.
28. Lee JL, Wang MJ, Sudhir PR and Chen JY: CD44 engagement promotes matrix derived survival through the CD44-SRC-integrin axis in lipid rafts. Mol Cell Biol 28: 5710-5723, 2008.
29. Jacobson K and Dietrich C: Looking at lipid rafts? Trends Cell Biol 9: 87-91, 1999.
30. Bauer N, Fonseca AV, Florek M, Freund D, Jászai J, Bornhäuser M, Fargeas CA and Corbeil D: New insights into the cell biology of hematopoietic progenitors by studying Prominin-1 (CD133). Cells Tissues Organs 188: 127-138, 2008.
31. Kyo S, Maida Y and Inoue M: Stem cells in endometrium and endometrial cancer: accumulating evidence and unresolved questions. Cancer Lett 308: 123-133, 2011.
32. Kokcu A: Relationship between endometriosis and cancer from current perspective. Arch Gynecol Obstet 284: 1473-1479, 2011.